邱海波医生个人简介
邱海波，主诊教授、医学博士、副主任医师、硕士生导师。医疗工作特长 胃肠肿瘤的综合治疗，尤其擅长胃癌、胃肠间质瘤的腹腔镜、机器人微创手术和开放手术，胃肠间质瘤的靶向治疗，胃癌的转化治疗。熟悉掌握四级手术（胃癌根治术、腹腔镜胃癌根治术、胰十二指肠切除术等），个人主刀超过1000余台高难度手术，连续多年在全国胃癌年会以及胃癌学习班进行手术直播和演示，全国腹腔镜胃癌手术大赛获得总冠军。教学 承担2010级、2014级、2018级中山医学院本科见习带教2014获得 中山大学肿瘤防治中心 英文授课比赛 三等奖中山大学硕士生导师，指导研究生数名学术活动 翻译NCCN胃肠间质瘤、胃癌指南，被NCCN指定为中文官方版。发起并成立中国胃肠间质瘤研究组（CN-GIST）国际大会演讲Haibo Qiu, Wei Zhuang, Xueding Wang, Shuang Xin, Min Huang, Zhiwei Zhou. Impact of pharmacogenomics on imatinib toxicity in gastrointestinal stromal tumors. ASCO Poster, June 2017. Chicago, US. (中国GIST领域唯一一项) Qiu Hai-Bo. Palliative Surgical resection for patients with the advanced Gastrointestinal Stromal Tumor. International Gastric Cancer Conference. Oral Presentation. April 2017 Beijing China.Qiu Hai-Bo. The Prognostic Significance of Peripheral T-lymphocyte Subsets and NK cells in Patients with Colorectal Cancer. 19th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists. Oral Presentation. September 24th 2009.
社会任职
中国临床肿瘤学年会(CSCO)胃癌指南英文版翻译小组组长中国临床肿瘤学年会(CSCO)翻译小组副组长,并长期担任CSCO年会,BOA等大型会议的同声传译、现场翻译。中国抗癌协会胃肠间质瘤青年委员会副主任委员CSCO 胃肠间质瘤专家委员会委员《NEJM医学前言》中文版翻译编辑《肿瘤学杂志》青年编委
获奖荣誉
2019 南中国腹腔镜胃癌手术视频比赛 二等奖2017 CSCO 35 under 35最具潜力肿瘤医生奖2017 GIST-TOUR 全国研究设计比赛 冠军2016 南中国胃肠间质瘤病例大赛 冠军2012 获教育部第一三共奖学金2012 中山大学优秀博士生
科研成果
主持或参与基金项目国家自然青年科学基金项目，81602061，JUN/Cyclin D1通路在胃肠间质瘤对伊马替尼耐药的作用及机制研究，2017/01-2019/12，17万，在研，主持。国家自然青年科学基金项目，81602143，TACC3介导肝癌射频消融治疗后转移复发的机制与干预策略，2017/01-2019/12，17万，在研，第二参与人。 国家自然科学基金面上项目，81372474、《抑制PREX2逆转胃肠道间质瘤对酪氨酸激酶抑制剂耐药的研究》、2014/01-2017/12、65万、已结题、第二参与人。 广州市科技计划，2014J4100179，新化合物逆转胃肠道间质瘤对酪氨酸激酶抑制剂耐药的研究，2014/01-2016/12，8万，在研、第二参与人。发表文章 (第一作者，通讯作者) Chen W#, Kuang Y#, Qiu HB#, Cao Z, Tu Y, Sheng Q, Eilers G, He Q, Li HL, Zhu M, Wang Y, Zhang R, Wu Y1, Meng F, Fletcher JA, Ou WB. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors. Cancer Res. 2017 Sep 15;77(18):5107-5117. IF 9.122 Zhang LY#, Wu JL#, Qiu HB#, Dong SS, Zhu YH, Lee VH, Qin YR, Li Y, Chen J, Liu HB, Bi J, Ma S, Guan XY, Fu L. PSCA acts as a tumor suppressor by facilitating the nuclear translocation of RB1CC1 in esophageal squamous cell carcinoma. Carcinogenesis. 2016 Mar;37(3):320-332. IF 5.105 Zhou ZG#, Chen JB#, Qiu HB#, Wang RJ, Chen JC, Xu L, Chen MS, Zhang YJ. Parecoxib prevents complications in hepatocellular carcinoma patients receiving hepatic transarterial chemoembolization: a prospective score-matched cohort study. Oncotarget. 2016 May 10;7(19):27938-45. IF 5.168 Xuechao Liu#, Haibo Qiu#, Yuying Huang, Dazhi Xu, Wei Li, Yuanfang Li, Yingbo Chen, Zhiwei Zhou*, Xiaowei Sun*. Impact of preoperative anemia on outcomes in patients undergoing curative resection for gastric cancer: a single‐institution retrospective analysis of 2163 Chinese patients. Cancer Med. 2018 Feb; 7(2): 360–369. IF 3.362Wei Zhuang#, Jing‐Dun Xie#, Shan Zhou, Zhi‐Wei Zhou, Yi Zhou, Xiao‐Wei Sun, Xiu‐Hong Yuan, Min Huang, Si Liu, Shuang Xin, Qi‐Biao Su, Hai‐Bo Qiu*, Xue‐Ding Wang*. Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients? Cancer Med. 2018 Feb; 7(2): 317–324. IF 3.362Seeruttun SR, Yuan S, Qiu HB#, Huang Y, Li Y, Liang Y, Guan Y, Zhan Y, Li W, Chen Y, Sun X, Xu D, Zhou Z. A comprehensive analysis comparing the eighth AJCC gastric cancer pathological classification to the seventh, sixth, and fifth editions. Cancer Med. 2017 Dec;6(12):2804-2813. IF 3.362 Liu X, Xu P, Qiu HB#, Xu D, Li W, Zhan Y, Li Y, Chen Y, Zhou Z, Sun X. Preoperative Nutritional Deficiency Is a Useful Predictor of Postoperative Outcome in Patients Undergoing Curative Resection for Gastric Cancer. Transl Oncol. 2016 Dec;9(6):482-488. IF 3.025 Liu X, Xu P, Qiu HB#, Liu J, Chen S, Xu D, Li W, Zhan Y, Li Y, Chen Y, Zhou Z, Sun X. Clinical utility of HER2 assessed by immunohistochemistry in patients undergoing curative resection for gastric cancer. Onco Targets Ther. 2016 Feb 26;9:949-58. IF 2.612 Hai-Bo Qiu#, Zhong-Guo Zhou#, Xing-Yu Feng#, Xue-Chao Liu, Jing Guo, Ming-Zhe Ma, Ying-Bo Chen, Xiao-Wei Sun*, Zhi-Wei Zhou*. Advanced gastrointestinal stromal tumor patients benefit from palliative surgery after tyrosine kinase inhibitors therapy. Medicine (Baltimore). 2018 Jan;97(2):e9097. IF 1.803Qiu HB#, Zhuang W#, Wu T, Xin S, Lin CZ, Ruan HL, Zhu X, Huang M, Li JL, Hou XY, Zhou ZW, Wang XD. Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1. Pharmacogenomics J. 2017 Aug 1. doi: 10.1038/tpj.2017.40. IF 3.815Liu X, Qiu HB#, Zhang P, Feng X, Chen T, Li Y, Tao K, Li G, Sun X, Zhou Z; China Gastrointestinal Stromal Tumor Study Group (CN-GIST). Prognostic role of tumor necrosis in patients undergoing curative resection for gastric gastrointestinal stromal tumor: a multicenter analysis of 740 cases in China. Cancer Med. 2017 Dec;6(12):2796-2803. IF 3.362 Liu X#, Qiu HB#, Zhang P, Feng X, Chen T, Li Y, Tao K, Li G, Sun X, Zhou Z; China Gastrointestinal Stromal Tumor Study Group (CN-GIST). Ki-67 labeling index may be a promising indicator to identify "very high risk" gastrointestinal stromal tumor (GIST): a multicenter retrospective study of 1022 patients. Hum Pathol. 2017 Sep 26. pii: S0046-8177(17)30345-3. IF 3.014 Liu X#, Qiu HB#, Liu J, Chen S, Xu D, Li W, Zhan Y, Li Y, Chen Y, Zhou Z, Sun X. A Novel Prognostic Score, Based on Preoperative Nutritional Status, Predicts Outcomes of Patients after Curative Resection for Gastric Cancer. J Cancer. 2016 Oct 25;7(14):2148-2156. IF 2.916 Zhuang W#, Qiu HB#, Chen XM, Yuan XH, Yang LF, Sun XW, Zhou XJ, Huang M, Wang XD, Zhou ZW. Simultaneous quantification of imatinib and its main metabolite N-demethyl-imatinib in human plasma by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring in patients with gastrointestinal stromal tumor. Biomed Chromatogr. 2017 Dec;31(12). IF 1.601Liu X, Qiu HB#, Kong P, Zhou Z, Sun X. Gastric cancer, nutritional status, and outcome. Onco Targets Ther. 2017 Apr 12; 10: 2107 - 2114. IF1.653Qiu HB#, Zhang LY#, Ren C. Targeting CDH17 suppresses tumor progression in gastric cancer by downregulating wnt/β-catenin signaling. PLoS One. 2013;8(3):e56959. IF 2.806Qiu HB#, Chen G, Keshari RP et.al. The extramural metastasis might be categorized in lymph node staging. BMC Cancer. 2011 Sep 26;11(1):414 IF 3.288Qiu HB#, Zhang LY#, Li YF et al. Ratio of Metastatic To Resected Lymph Nodes Enhances To Predict Survival In Patients With Stage III Colorectal Cancer. Ann Surg Oncol. 2011 Jun;18(6):1568-74. IF 4.041Qiu HB#, Zhang LY#, Zeng ZL, et.al. HBV infection decreases risk of liver metastasis in patients with colorectal cancer: A cohort study. World J Gastroenterol. 2011 Feb 14;17(6):804-8. IF 3.365Qiu HB#, Zhang LY#, Keshari RP et.al. Relationship between H.Pylori Infection and Clinicopathological Features and Prognosis of Gastric Cancer. BMC Cancer. BMC Cancer. 2010 Jul 17;10:374. IF 3.288Qiu HB#, Wu XJ#, Zhou ZW, et.al. The Prognostic Significance of Peripheral T-lymphocyte Subsets and NK cells in Patients with Colorectal Cancer. Hepatogastroenterology. 2009 Sep-Oct;56(94-95):1310-5. IF 1.012邱海波，周志伟. NCCN胃癌临床实践指南2017年第五版更新要点解读.中华胃肠外科杂志.2018 Feb 21(2) 160-164邱海波、张鹏、冯兴宇、陈韬、孙晓卫、余江、陈志京、李勇、陶凯雄、李国新、周志伟.中国四家医疗中心胃肠间质瘤诊断与治疗的18年变迁. 中华胃肠外科杂志.2016 Nov.19(11)1265-1270 邱海波、庄玮、王雪丁、黄民、周志伟.胃肠间质瘤患者遗传因素与伊马替尼药动学个体差异的相关性研究.中华胃肠外科杂志2017 Sept.20(9)1031-1034邱海波、孙晓卫、周志伟.胃肠间质瘤辅助治疗研究新进展.中华胃肠外科杂志.2017 Sept.20(9)961-965 邱海波、陈功、周志伟.胃肠间质瘤研究进展.中国普通外科杂.2017 Apr.26(4)1-6 邱海波、周志伟. 大数据时代胃肠间质瘤研究的使命. 中国普外基础与临床杂志. 2017 Feb 24(2) 1-5 邱海波, 伍小军，周志伟，等. 结直肠癌患者外周血T淋巴细胞亚群和NK细胞数目的变化及其临床意义. 广东医学. Mar.2009,Vol.30,No.3,64-66邱海波, 杨炜青，林泽英，等. 卡维地洛对异丙肾上腺素诱导小鼠心肌缺血的保护作用. 广东医学. 2009,July, supplement(1)论文摘要Haibo Qiu, Zhongguo Zhou, Xingyu Feng, Xiaowei Sun, Yingbo Chen, Yuanxiang Guan, Dazhi Xu, Yuanfang Li, Wei Li, Youqing Zhan, Rui-hua Xu, Zhiwei Zhou. Results of long-term follow-up for patients with advanced gastrointestinal stromal tumor underwent palliative surgery after tyrosine kinase inhibitors therapy. Journal of Clinical Oncology 34, no. 15_suppl IF 24.008Haibo Qiu, Wei Zhuang, Ting Wu, Min Huang, Zhiwei Zhou, Xueding Wang. Next generation sequencing (NGS) in wild type GISTs. Journal of Clinical Oncology 35, no. 15_suppl IF 24.008
工作经历
2018年1月-至今中山大学肿瘤防治中心 胃外科副主任医师
2016年1月-2017年12月中山大学肿瘤防治中心 胃外科主治医师
2013年8月-2015年12月中山大学肿瘤防治中心 胃胰科医师
教育经历
博士中山大学肿瘤防治中心&哈佛大学医学院肿瘤学
硕士中山大学肿瘤防治中心肿瘤学
本科广州医学院临床医学
